CTLA4 and melanoma: Several clinical studies have demonstrated that cancer patients with high TMB show enhanced response to treatment with immune checkpoint inhibitors such as anti-CTLA-4 therapy for melanoma (36), anti-PD-L1 therapy for uroepithelial cancer (39), and anti-PD-1 therapy for non-small cell lung cancer and colorectal cancer (40).